This inventor holds 1 USPTO granted patent. Top assignee: The University of Texas System. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: Rakesh K Tyagi: Innovator in Estrogen Receptor Research
Introduction
Rakesh K Tyagi is a notable inventor based in New Delhi, India. He has made significant contributions to the field of biomedical research, particularly in the area of estrogen-dependent tumors. His innovative work has the potential to impact cancer treatment and improve patient outcomes.
Latest Patents
Rakesh K Tyagi holds a patent for "Estrogen receptor site-specific ribozymes and uses thereof for estrogen dependent tumors." This patent describes highly specific hammerhead ribozymes that target human estrogen receptor mRNA. The ribozymes, designated RZ1 through RZ7, provide predictable mRNA cleavage products. The methods outlined in the patent aim to inhibit estrogen-dependent tumor growth, such as that characteristic of breast cancer. Both ribozymes can be used together or separately with equal efficiency. The ribozymes possess a sequence region with a catalytic core that provides the attributed catalytic activity.
Career Highlights
Rakesh K Tyagi is affiliated with the University of Texas System, where he continues to advance his research. His work focuses on developing innovative solutions for complex medical challenges, particularly in oncology.
Collaborations
Rakesh has collaborated with notable colleagues, including Yan Lavrovsky and Chung S Song. These collaborations have further enriched his research and contributed to the advancement of knowledge in his field.
Conclusion
Rakesh K Tyagi's contributions to the field of biomedical research, particularly through his patent on estrogen receptor site-specific ribozymes, highlight his innovative spirit and dedication to improving cancer treatment. His work continues to inspire future research and development in this critical area of health.